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Abstract
Background: This study systematically compares newspaper coverage of clinical trials for herbal
remedies, a popular type of complementary and alternative medicine, with clinical trials for
pharmaceuticals using a comparative content analysis. This is a timely inquiry given the recognized
importance of the popular press as a source of health information, the complex and significant role
of complementary and alternative medicine in individual health-care decisions, and the trend
toward evidence-based research for some complementary and alternative medical therapies. We
searched PubMed for clinical trials, Lexis/Nexis for newspaper articles in the UK, US, Australia/
New Zealand, and Factiva for Canadian newspaper articles from 1995 to 2005. We used a coding
frame to analyze and compare 48 pharmaceutical and 57 herbal remedy clinical trials as well as 201
pharmaceutical and 352 herbal remedy newspaper articles.
Results: Herbal remedy clinical trials had similar Jadad scores to pharmaceutical trials but were
significantly smaller and of shorter duration. The trials were mostly studies from Western
countries and published in high-ranking journals. The majority of pharmaceutical (64%) and herbal
remedy (53%) clinical trials had private sector funding involvement. A minority declared further
author conflicts of interest. Newspaper coverage of herbal remedy clinical trials was more negative
than for pharmaceutical trials; a result only partly explained by the greater proportion of herbal
remedy clinical trials reporting negative results (P = 0.0201;  2 = 7.8129; degrees of freedom = 2).
Errors of omission were common in newspaper coverage, with little reporting of dose, sample size,
location, and duration of the trial, methods, trial funding, and conflicts of interest. There was an
under-reporting of risks, especially for herbal remedies.
Conclusion: Our finding of negative coverage of herbal remedy trials is contrary to the positive
trends in most published research based primarily on anecdotal accounts. Our results highlight how
media coverage is not providing the public with the information necessary to make informed
decisions about medical treatments. Most concerning is the lack of disclosure of trial funding and
conflicts of interest that could influence the outcome or reporting of trial results. This lack of
reporting may impact the medical research community, which has the most to lose by way of public
trust and respect.
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Background
Health care receives significant media attention, and com-
plementary and alternative medicine (CAM) is no excep-
tion [1-3]. Given the continued public interest in CAM,
this media attention is hardly surprising. Indeed, CAM is
a multibillion dollar business [4]. An increasingly
empowered [5] and informed public continues to turn to
CAM as an alternative or supplement to conventional
medical therapies [6], even though the mechanisms of
action are not always well understood, efficacy is often
unsupported by research, and use has been associated
with adverse reactions [7-9]. There are varied explanations
for the appeal of CAM, such as belief in a particular phil-
osophical orientation towards health and life, general dis-
satisfaction with conventional medicine, and belief that it
is natural and therefore, less harmful than biomedical
treatments [10].
In this paper we explore the nature and tone of newspaper
coverage of clinical trials for herbal remedies, and com-
pare it with coverage of clinical trials for pharmaceuticals
used to treat the same medical conditions. Given the rec-
ognized importance of the popular press as a source of
health information [11,12], the complex and significant
role of CAM in individual health-care decisions, and the
trend toward evidence-based research for some CAM ther-
apies [13-15], this seems a timely investigation. We exam-
ine, through a comparative content analysis, the quality of
information provided by newspapers about one type of
news story about CAM: clinical trials and their outcomes,
recognizing that reporting the results of clinical trials does
not represent the majority of news coverage on CAM. This
type of study, comparing media coverage with the scien-
tific research it covers is a well recognized method in
media studies [16]. Is the tone of reporting different for
herbal remedy versus pharmaceutical clinical trials? Are
there differences in the sources of trial funding and the
reporting of that issue? What about the reporting of con-
flicts of interest? This latter question seems particularly
important as real or perceived conflicts of interest may
diminish public trust in medical research [17].
Methods
We first searched Lexis/Nexis for newspaper articles in the
United Kingdom and Ireland (UK), the United States
(US), and Australia/New Zealand and Factiva for newspa-
per articles in Canada using the search term '(herb or
herbal) and remedy and "clinical trial"' from 1 January
1995 to 1 June 2005. This search strategy identified Eng-
lish language news articles that used both the term 'clini-
cal trial' and 'herb/herbal'. We started with newspaper
articles and not the clinical trials because few herbal rem-
edy clinical trials receive media coverage. We retained all
articles that discussed the results of an identifiable, pub-
lished clinical trial. As many newspaper articles do not use
the expression 'clinical trial' but instead use terms such as
'study', we also conducted specific searches on Lexis/Nexis
and Factiva for additional newspaper articles on each clin-
ical trial using different combinations of search terms,
including journal name, author name(s), herbal remedy
tested, and lead research institution. We omitted duplicate
newspaper articles, selecting the article with highest word
count, to take into account the effect of syndicated articles
and newswires. We identified and collected the published
clinical trials using Google searches and PubMed.
Two project-naïve, undergraduate student coders used a
standardized coding frame, a common method for ana-
lyzing media coverage [18-21] for clinical trials (Appendix
1), to assess: journal name, year, type of institution where
research was conducted, medical condition (using ICD-9-
CM: International Classification of Diseases, 9th revision,
Clinical Modification), dose, location of clinical trial,
framed as controversy, benefits, risks, quality of the trial
(Jadad score) [22], sample size, length of trial, conflicts of
interest, trial funding, tone of clinical trial outcome, and
overall tone of the discussion/conclusions, taking into
account study limitations. For newspaper articles, the cod-
ers assessed the newspaper, country, year, word count,
news format, themes, name of treatment, doses tested, use
specified, main voice, location of clinical trial, framed as
controversy, benefits, risks, conflicts of interest, funding
of clinical trial, involvement of funding agency, how con-
flict of interest is viewed, tone of assessment of clinical
trial outcomes, framing, accuracy, and, overall, whether
the main claims in the newspaper article reflected the
research findings.
The coders were first trained to use the coding frame by
the lead author and then worked together under supervi-
sion for 2 weeks. If discrepancies arose, the coders reached
a common interpretation and kept a log of decisions. The
coders then individually coded the remaining articles
(70% and 20%, respectively) with approximately 10%
overlap to calculate inter-coder reliability, using Kappa
scores. The coders reconvened periodically to discuss
issues that had arisen during coding. The median of
Kappa scores for clinical trials was 0.85 (range 0.39–1.00;
N = 12) and for newspaper articles was 0.71 (range 0.47–
1.00; N = 16), indicating good to excellent agreement.
Independent variable Kappa scores were between 0.65
and 1.00.
One author (HB) with expertise in pharmacology identi-
fied corresponding pharmaceuticals for each medical con-
dition identified in the coded herbal remedy clinical trials.
We conducted searches on Lexis/Nexis and Factiva as
above for newspaper coverage of identifiable clinical trials
of the pharmaceuticals. As significantly more pharmaceu-
tical trials received press coverage, we randomly selectedBMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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up to three clinical trials per medical condition and then
repeated the specific newspaper searches and coding
methodology as above.
Statistical analysis
We performed a classification tree analysis, using CART
Pro, version 6.0 to focus our analysis on the most impor-
tant variables [18]. The independent variables for clinical
trials were 'overall tone' and the 'tone of clinical trial out-
comes' and for newspaper articles were 'overall tone' and
'tone of assessment of the trial'. The classification tree
used twoing for ranked data as the splitting method and
determined which variables from the coding frame were
most important in assigning a newspaper article or clini-
cal trial to one of the three categories of tone (negative,
neutral, positive). The most important variables for both
measures of tone for clinical trials were length of trial,
sample size, year, total number of benefits, total number
of risks/costs, and Jadad score. The most important varia-
bles for both measures of tone for newspaper articles were
word count, year, total number of benefits, and total
number of risks/costs. We also selected additional varia-
bles of interest: for clinical trials, conflicts of interest and
type of funding, and for newspaper articles, medical con-
dition, conflicts of interest, and type of funding. National
differences were not important and, therefore, the data
from the different countries were combined.
We compared the distributions of the two measures of
tone for clinical trials and newspaper articles between
treatment type: herbal remedy or pharmaceutical using χ-
squared test. We then used two sample Wilcoxon tests to
compare the selected continuous variables between
herbal remedies and pharmaceuticals for both clinical tri-
als and newspaper articles. In addition, we compared the
remaining variables presented in Table 1 using χ-square
analysis. All tests were two-sided, and we considered P val-
ues of 0.05 or lower as statistically significant.
Finally, we used logistic regression (multinomial for tone
of assessment of the trial) adjusting for covariates that
showed a significant difference using Wilcoxon tests to
compare the measures of tone between herbal remedies
and pharmaceuticals for clinical trials and newspaper arti-
cles. Results are presented as odds ratios and 95% confi-
dence intervals where appropriate. All analyses were done
in Stata version 7.0 (Stata Corporation, College Station,
US).
Table 1: Coding variables for clinical trials of herbal remedies and pharmaceuticals and associated newspaper articles
Coding variable: clinical trials Herbal remedy clinical trial
(N = 57)
Pharmaceutical clinical trial
(N = 48)
Statistical significance
Mean number of benefits 1.6 1.4 NS
Mean number of risks 0.9 1.1 NS
Mean sample size 144 12,124 P < 0.0001
Mean duration of trial (days) 124 1435 P = 0.008
Mean Jadad score 3.2 3.1 NS
Dose specified 94.7% 72.9% P = 0.002
Trial described as randomized 78.9% 72.9% P = 0.001
Trial described as double-blind 71.9% 68.8% P < 0.001
Withdrawals and dropouts described 82.5% 79.2% NS
Conflicts of interest NOT specified 77.2% 50.0% P = 0.003
Funding of trial NOT specified 33.9% 8.3% P = 0.004
Coding variable: newspaper articles (N = 352) (N = 201)
Mean word count 698 716 NS
Mean number of benefits 1.3 1.2 NS
Mean number of risks 0.53 1.3 P < 0.0001
Source of funding NOT specified 83.5% 81.6% NS
Conflicts of interest NOT specified 96.6% 96.0% NS
At least one scientific/technical error in reporting 
on the trial
99% 99% NS
Duration of the clinical trial NOT specified 59.7% 57.2% NS
Sample size NOT specified 41.5% 29.4% P < 0.0001
Dose NOT specified 81.0% 95.5% P < 0.0001
Location of trial NOT specified 32.1% 32.3% NS
Randomization NOT specified 89.2% 94.0% NS
Double-blinding NOT specified 90.3% 98.5% P < 0.0001
Use of placebo NOT specified 45.7% 72.6% P < 0.0001
Withdrawals/dropouts NOT specified 98.0% 97.5% NS
NS = not significantBMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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Methodological limitations
Our methods have a number of limitations. First, we sur-
veyed only the print media, while television and increas-
ingly the Internet are likely important sources of
information for the public. We did, however, survey a
broad range of newspapers of varying quality. Second, our
study was limited to the small subset of newspaper stories
that were directly related to peer-reviewed clinical trials.
However, this met our objective to assess whether media
coverage of the evidence-based trend in CAM was qualita-
tively different from reporting on conventional medicine
with a long-standing tradition of clinical trial research.
Finally, our study is a content analysis using an a priori
coding frame [18-21], not a more detailed qualitative tex-
tual analysis. This enabled us to survey a larger number of
clinical trials and newspaper articles and to test for statis-
tically significant differences in reporting trends.
Results
We coded 105 clinical trials (48 pharmaceutical, 57
herbal remedy) and 553 associated newspaper articles
(201 pharmaceutical, 352 herbal remedy). The main com-
parisons are for tone (positive, neutral, negative), quality
measures, and content between the herbal remedy and
pharmaceutical clinical trials. There are four measures of
tone: the tone of the results/outcomes of the clinical trial;
the overall tone of the clinical trial, taking into account
limitations and the discussion; the tone of the assessment
of the specific clinical trial in the newspaper article; and
the overall tone of the entire newspaper article.
Clinical trials: herbal versus pharmaceutical
The clinical trials were published in 39 journals, primarily
JAMA, the journal of the American Medical Association
(21), the Lancet  (14), New England Journal of Medicine
(13), and BMJ (9). JAMA (10) and BMJ (8) published the
greatest number of herbal remedy clinical trials reported
in newspapers. Only one herbal remedy clinical trial was
published in a CAM-specific journal, the Journal of Alterna-
tive and Complementary Medicine, confirming the trend for
newspapers to report research in mainstream, high-
impact medical journals. The majority of trials took place
in North America, the UK and Europe, and the majority
was conducted in public sector research institutions with
only two pharmaceutical and four herbal remedy clinical
trials taking place in the private sector.
The majority of pharmaceutical clinical trials were funded
by the private sector (33%) or by mixed private and public
funding (31%), but a minority of trials reported authors
with conflicts of interest (Figure 1). Conflicts of interest
were either not specified (50%) or there was a declaration
of no conflict (4%). Of the pharmaceutical clinical trials,
46% declared conflicts of interest by authors, or these
were obvious from the publication, generally because one
or more of the authors were employed by the company
that funded the trial (Figure 1). In comparison, 34% of
herbal remedy clinical trials did not specify the source of
funding. Those that did were funded by the private sector
(30%) or through mixed public and private funding
(23%). Very few herbal remedy clinical trials specified any
further conflicts of interest; conflicts were either declared
or obvious in 23%.
There was a significant association between tone of clini-
cal trial outcomes and type of clinical trial (P = 0.0201;  2
= 7.8129; degrees of freedom (DF) = 2) and between over-
all tone and type of clinical trial (P = 0.0230;  2 = 7.5462;
DF = 2) (Figure 2). Most trials had a positive valuation of
outcome, meaning that the trials were reporting positive
results. However, a greater proportion of CAM clinical tri-
als reported negative results (Figure 2). These associations
are no longer significant using multinomial logistic
regression after adjusting for significant covariates: length
of trial and sample size (Table 1).
Newspaper articles: herbal versus pharmaceutical
We coded articles from 131 newspapers in five countries.
Newspapers with more than ten articles on herbal remedy
clinical trials were the Daily Mail (UK), the Kitchener-
Funding and conflicts of interest Figure 1
Funding and conflicts of interest. Comparison of the 
funding and conflicts of interest between herbal remedy clini-
cal trials and pharmaceutical clinical trials.BMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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Waterloo Record (Canada), the New York Times (US), the
Washington Post (US), Pittsburgh Post-Gazette (US), and The
Record (US). The majority of newspaper articles were pub-
lished in the US (296), followed by the UK (151), Canada
(100), and Australia/New Zealand (6). Most newspaper
articles were reporting on the latest news (60%) and one
third had a longer, investigative reporting format where
the clinical trial was only one part of the article. The pre-
dominance of straight news reporting was reflected in
whether the article was framed as a controversy: 43% of
articles had no controversial element, 35% were framed as
a balanced controversy, and 22% as an imbalanced con-
troversy.
The main theme of almost all the articles on pharmaceu-
tical clinical trials was the trial itself. This contrasted with
articles on herbal remedy clinical trials where 63.6%
focused on the trial and the other third focused on the
medical condition, the myriad of uses for an herb, and the
health risks associated with herbal remedies. The main
benefit cited in almost all articles (90%) was improved
health or treatment options, and only 4% cited no bene-
fits. However, 54% of articles did not quantify the likeli-
hood of the benefit. Interestingly, 29% of articles on
herbal remedy versus 4% of pharmaceutical clinical trials
stated there was no benefit. The main individual inter-
viewed or quoted in the articles for both pharmaceutical
clinical trials (63%) and herbal remedy clinical (73%) tri-
als was a university or hospital scientist or physician not
specializing in CAM. Indeed CAM researchers or practi-
tioners were cited in only 8% of articles on herbal remedy
clinical trials.
There were strong associations in newspaper articles
between the tone of valuation of the results of the clinical
trial and the type of trial (P < 0.0001;  2 = 135.5; DF = 2)
and the overall tone of the newspaper article and the type
of trial (P < 0.0001;  2 = 56.1; DF = 2). Newspaper articles
were more highly polarized with respect to evaluating the
outcomes of herbal remedy clinical trials than for phar-
maceutical clinical trials. For pharmaceutical trials, the
evaluation was most likely to be positive or neutral (Fig-
ure 2), while a greater proportion of newspaper articles
evaluated the outcomes of herbal remedy clinical trials
negatively.
The difference in overall tone of the newspaper article,
where the clinical trial may have been only one part of a
larger story was even more pronounced. The overall tone
of the newspaper article was most likely to be positive
(68.2%) or neutral (31.8%) when reporting on pharma-
ceuticals. Indeed no articles on pharmaceutical clinical tri-
als had a negative overall tone. In contrast, 21.9% of
articles on herbal remedy clinical trials had an overall neg-
ative tone, while the majority were neutral (57.1%), and
21% were positive (Figure 2). This is so, even though the
articles reported significantly more risks, primarily
adverse effects, associated with pharmaceuticals than
herbal remedies (Figure 2). However, 40% of articles over-
all did not specify a risk, and 53% of those which did spec-
ify a risk did not quantify the likelihood of that risk. There
were no significant associations between type of trial and
conflicts of interest and type of funding of the trial; 83%
of articles did not mention the source of funding for the
trial and 96% did not specify the involvement of the
funder. Similarly, 96% did not report on conflicts of inter-
est. However, of the 29 articles that did report on conflicts
of interest, 38% viewed the conflict negatively while 48%
were neutral in their evaluation of the conflict.
The significant associations for overall tone remained
when we used logistic regression and adjusted for signifi-
cant covariates, year, and total number of risks. We calcu-
lated significance of overall tone for positive and neutral
valuation categories only because one cell (negative valu-
ation of pharmaceutical clinical trials) had zero counts
(odds ratio = 13.210; 95% Wald confidence limits 7.414–
23.539; P < 0.0001). We present the probabilities for tone
of assessment of clinical trial outcomes adjusted for signif-
icant covariates because of the difficulties in interpreting
multinomial logistic regression outputs (type of clinical
Tone of clinical trials and related newspaper articles Figure 2
Tone of clinical trials and related newspaper articles. 
Comparison for the tone (positive, neutral, negative) of 
herbal remedy and pharmaceutical clinical trials and the 
newspaper articles reporting on those trials. There are four 
measures of tone: the tone of the results/outcomes of the 
clinical trial; the overall tone of the clinical trial, taking into 
account limitations and the discussion; the tone of the assess-
ment of the specific clinical trial in the newspaper article; and 
the overall tone of the entire newspaper article.BMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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trial: P < 0.0001;  2 = 41.26; DF = 2; year: P < 0.0001;  2 =
85.84; DF = 182; total risks: P < 0.0001;  2 = 19.19; DF =
2).
For all newspaper articles, there is a significant association
between the type of medical condition and both of the
measures of tone (overall: P < 0.0001,  2 = 9.5, DF = 12;
tone of assessment of the trial: P < 0.0001,  2 = 41.7, DF =
12). The largest categories of medical conditions were dis-
eases of the genitourinary system (mainly erectile dys-
function and menopause), a range of diseases affecting
organ systems and mental disorders (mainly depression).
Proportionally, the most negative overall tone was
reserved for disorders associated with diet and obesity.
The tone of assessment of the trial itself was proportion-
ally most negative for diseases of the genitourinary system
(mainly erectile dysfunction and menopause), mental dis-
orders (mainly depression), and infectious diseases
(mainly HIV/AIDS).
Discussion
As CAM use increases alongside concerns about evidence
of efficacy, we are interested in how the media, a signifi-
cant source of medical information for the lay public and
some professionals, report on clinical trials. This is the
first study to compare systematically newspaper coverage
of clinical trials for herbal remedies, a popular type of
CAM, with clinical trials for pharmaceuticals. There has
been a large increase in the number of clinical trials for
herbal remedies over the last 20 years [23], the vast major-
ity published in specialized journals on traditional Chi-
nese medicines [24]. There has not, however, been a
concomitant increase in the number of media articles
reporting on clinical trials for herbal remedies; overall the
media is not reporting on the trend toward evidence-
based herbal medicine [23].
Those herbal remedy clinical trials that receive newspaper
coverage are of similar quality to pharmaceutical clinical
trials, likely reflecting the media's preference towards
studies conducted in Western countries [24], and a select
number of high-ranking journals for most coverage of
medical research [25]. Our Jadad scores are marginally
higher than those calculated for a greater variety of CAM
trials published in a broader range of journals [24].
Another study comparing herbal remedy and pharmaceu-
tical clinical trials conducted in Western countries also
found no difference in quality of described methods [25].
Assessing reported methodology within clinical trials,
however, may be an incomplete proxy for quality since
methodology is often significantly abbreviated or pub-
lished in accompanying longer articles [25]. In that case,
sample size and duration of the study could be a more
precise measure of trial quality [25], in which case, phar-
maceutical clinical trials are significantly larger; many
herbal remedy clinical trials had fewer than 100 patients
and were of short duration.
Our results suggest high-impact journals publish a signif-
icant number of CAM studies with negative results
[26,27], even though the general trend toward favoring
positive results applies to both types of clinical trial [28].
Overall, however, the tone of both the positive and nega-
tive clinical trials is tempered in the discussion by high-
lighting, for example, trial limitations or conversely,
potential for future research.
Despite the overall positive results and tone of the clinical
trials, newspaper coverage of herbal remedy clinical trials
was more negative than for pharmaceutical clinical trials.
This is contrary to most published research on media cov-
erage of CAM. Those studies consider a much broader
spectrum of treatments and the media content is generally
anecdotal rather than evidence based [29]. Indeed, jour-
nalists are displaying a degree of skepticism rare for med-
ical reporting [23]. It is possible that once confronted with
actual evidence, journalists are more critical or skeptical.
It may be considered more newsworthy to debunk com-
monly held beliefs and practices related to CAM, to go
against the trend of positive reporting in light of evidence.
It is also possible that journalists who turn to press
releases of peer-reviewed, high-impact journals have sub-
tle biases towards scientific method and conventional
medicine. Also, journalists turn to trusted sources in the
biomedical community for comments on clinical trials,
both herbal and pharmaceutical, potentially leading to a
biomedical bias in reporting trial outcomes. Finally, the
minority of newspaper articles were written by named
journalists. Since it was not possible to identify the
authors of the majority of newspaper stories, it is possible
that some journalists with either a positive or negative
bias contributed disproportionately to the news coverage.
Implications of results
Despite repeated studies, the media continues to provide
insufficient information to the public largely through
omission, an under-reporting of risk, and a lack of disclo-
sure of trial funding and potential conflicts of interest. The
latter is true for both pharmaceuticals and herbal reme-
dies but may be more critical for herbals, which may be
accessed by the lay public without a physician intermedi-
ary.
Media coverage is not providing the public with the infor-
mation necessary to make informed decisions about med-
ical treatments, either conventional or alternative. There
are significant errors of omission of basic information
such as dose, sample size, location and duration of the
trial, and methods for randomized clinical trials. In addi-
tion, there is an under-reporting of risks, especially in theBMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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context of herbal remedies. This is common in the context
of medical reporting where difficulties stem from a lack of
comprehension, both by the public and journalists, of dif-
ferences between absolute and relative risks and the
nature of probabilistic analyses [30]. Many studies have
reported on such errors of omission [18-20], citing space
and time constraints of medical journalists whose stories
compete for publication and the attention of editors with
general news and other content [19,31].
The media is also overly reliant on narratives from satis-
fied patients, researchers, clinicians, and patient groups
without disclosing financial ties to industry and conflicts
of interest [20,21,32]. 'Conflicts occur when scientists are
expected to exercise judgment dispassionately but instead
are motivated by financial, professional, or other types of
interest' [33]. There has been an international movement
toward reporting of funding and conflicts of interest in
published clinical trials, yet a significant portion of herbal
remedy clinical trials in our study did not disclose any
funding source. Those that did showed substantial fund-
ing from the private sector, not surprising considering the
current economics of CAM and interest in CAM by phar-
maceutical companies. Even more concerning was the
lack of disclosure of conflicts of interest, either positive or
negative, for both types of clinical trials. This suggests the
need for better implementation of funding and conflicts
of interest disclosure policies by medical journals [34].
The media should be encouraged to disclose the interests
of researchers and institutions involved in clinical trials
that could influence the outcome or reporting of trial
results [33]. Without such information, which our study
shows is largely missing from media coverage, it is not
possible for the lay public to assess the credibility of the
research. This lack of reporting should be of great concern
to the medical research community, which has the most
to lose by way of public trust and respect. Academic
researchers and institutions have the most to gain from
the development and enforcement of full disclosure
guidelines for both medical publications and for the
media.
Overall concerns have lead to suggestions for minimum
standards and content for medical coverage [32]. Gary
Schwitzer and colleagues [32] have argued ' [j]ournalists
have a special responsibility in covering health and medi-
cal news' knowing that 'readers and viewers may make
important health-care decisions based on the information
provided [in media stories]'. In response, solutions must
be aimed at all three major stakeholders and involve
guidelines for journalists [35] and increased training in
health and science journalism [20], increased training in
media communication skills for clinical researchers [36-
38], and scientific and media literacy programs for the lay
public [39]. Given the well-established and expanding
market for health coverage, it is time for journalists and
editors to experiment with improving content without
necessarily sacrificing narrative themes such as human-
interest stories. A change for the better is unlikely to result
in a reduced public appetite for health news – an appetite
that is increasingly sophisticated and desirous of high
quality information [40].
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Appendix
Appendix 1: Coding frame for clinical trials
1. Basic information
a. Trial number
b. Type of clinical trial (Pharmaceutical = 1; CAM = 2)
c. Journal name
d. Year
e. Type of institution where research conducted (lead or
corresponding author)
Not specified 0
University/hospital 1
Not-for-profit organization 3
Mixed 4
Private 5
Government 6
2. Contents
a. Medical condition
Not specified 0
Type of medical conditionBMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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b. Dose(s) specified (0 = no; 1 = yes)
c. Location of clinical trial
Not specified 0
US 1
Canada 7
UK 2
Europe 3
Australia 4
South America 5
Asia 6
International 8
Mid East/Africa 9
d. Is the article framed as a controversy? (no) 1
If yes, is the report
balanced 2
or imbalanced 3
e. Type of main benefit
Not specified 0
None (stated that there is no benefit) 1
Basic research 2
Improved health/treatment 3
Decreased side-effects 4
General safety 5
Increased autonomy/empowerment 6
Spiritual, moral, ethical 7
Environmental/ecological/nature 8
Economic 9
Improved quality of life 10
Other (specify) 11
f. Likelihood of benefit
Not specified 0
High 1
Moderate 2
Low 3
No benefit (stated) 4
Mentioned but not quantified 5
g. Total number of benefits mentioned number
h. Type of main risk/cost
Not specified 0
None (stated that there is no risk) 1
Basic research 2
Health 3
Increased side-effects 4
General safety 5
Decreased autonomy/empowerment 6
Spiritual, moral, ethical 7
Environmental/ecological/nature 8
Economic 9
Decreased quality of life 10
Other (specify) 11
i. Likelihood of risk/cost
Not specified 0
High 1
Moderate 2
Low 3
No risk/cost (stated) 4BMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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Mentioned but not quantified 5
j. Total number of risks/costs mentioned number
3. Quality of clinical trial
a. Was the study described as randomized (this includes
the use of words such as randomly, random and randomi-
zation? (no = 0; yes = 1)
b. Was the study described as double blind? (no = 0; yes
= 1)
c. Was there a description of withdrawals and dropouts?
(no = 0; yes = 1)
d. What was the Jadad score for quality of clinical trial?
(score 1–5)
e. What was the sample size?
f. What was the length of the clinical trial (days)?
4. Conflicts of interest
Not specified 0
Mentioned but none 1
Declared or obvious 2
5. Funding of the trial
Not specified 0
Public 1
Private 2
Mixed 3
6. Judgments and ratings
a. Tone of clinical trial outcome
Negative valuation of results 1
Positive valuation of results 2
Neutral valuation of results 3
b. Overall tone of discussion/conclusions, taking into
account study limitations
Negative valuation 1
Positive valuation 2
Neutral valuation 3
Explanation of coding frame for newspaper articles
7. Basic information
a. Trial and newspaper number
b. The name of the newspaper/country of newspaper
Australia/New Zealand 1
Canada 2
UK/Ireland 3
USA 4
c. Year of the newspaper article
8. Attention structure
With these variables we are measuring the editorial
importance of an article; the means used to attract the
reader's attention.
a. Word count
b. News format
(here we are attempting to distinguish between facts
and opinion)
Not specified 0
Article with latest news 1
Investigation, reportage, background 2
Interview (mainly) 3
Column, commentary by regular columnist 4
Editorial (paper's editor) 5
Commentary from other people (e.g. politicians,
religious leaders, special interest groups) 6
Letters to the editor 7
Review of books, films, etc. 8
Other 9BMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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9. Contents
a. Main theme
Science/medicine
Clinical trial 1
Meta-analysis of clinical trials 2
Medical condition  3
Review of treatments for a medical condition 4
Review of uses of a particular herb 5
Safety/risks
Health risks: CAM   6
Health risks: traditional medicine   7
Other risks: CAM 8
Other risks: traditional medicine   9
Other issues
Patenting, property rights   10
Economic prospects, opportunities   11
Biopharmaceutical industry   12
CAM industry   13
Biodiversity/conservation  14
Legal/regulatory  15
Science policy   16
Education  17
Public opinion (e.g. survey results)   18
Public protest/demonstration   19
Ethical issues   20
Religious issues   21
b. Name of herbal remedy/remedies or name of phar-
maceutical/traditional medicine(s)
(no = 0; yes = 1)
c. Dose(s) tested (no = 0; yes = 1)
d. Use specified (no = 0; yes = 1)
e. Main voice (who/what is the main spokesperson/
group/institution quoted or described)
Not applicable, unknown   0
Public sector
Parliament/congress  1
Government
General  2
Health  3
Industry  4
Environment  5
Patent Offices   6
Government research institutions/scientists (e.g.
National Institutes of Health)   7
Specialist CAM researcher/practitioner   8
Non-CAM university or hospital scientists/
physicians 9
Ethics committees   10
Judicial, legal voice   11
The public, public opinion (e.g. surveys)   12
The media, published opinion   13
Celebrity (sports, film TV)   14
Private sector – business
Scientists in private laboratories   15
Pharmaceutical company/spokesperson   16
CAM company spokesperson   17
Venture capital   18BMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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Private investors 19
Stock Exchange   20
Private sector – other
Political parties   21
Religious organizations   22
Consumer groups   23
Patient groups/lobbies   24
Environmental organizations   25
Professional organizations (medical, legal, etc.)
26
International institutions
Developing countries   27
European Union   28
European Parliament   29
United Nations organizations   30
Other international organizations   31
f. Location of clinical trial stated (no = 0; yes = 1)
g. Is the article framed as a controversy? (no) 1
If yes, is the report
balanced 2
or imbalanced 3
h. Type of main benefit
Not specified 0
None (stated that there is no benefit) 1
Basic research 2
Improved health/symptoms/condition 3
Decreased side-effects 4
General safety 5
Increased autonomy/empowerment 6
Spiritual, moral, ethical 7
Environmental/ecological/nature 8
Economic 9
Improved quality of life   10
Other (specify) 11
i. Likelihood of benefit
Not specified 0
High 1
Moderate 2
Low 3
No benefit (stated) 4
Mentioned but not quantified 5
j. Total number of benefits mentioned number
k. Type of main risk/cost
Not specified 0
None (stated that there is no risk) 1
Basic research 2
Health/symptoms/condition 3
Increased side-effects 4
General safety 5
Decreased autonomy/empowerment 6
Spiritual, moral, ethical 7
Environmental/ecological/nature 8
Economic 9
Decreased quality of life 10
Other 11
l. Likelihood of risk/costBMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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Not specified 0
High 1
Moderate 2
Low 3
No risk/cost (stated) 4
Mentioned but not quantified 5
m. Total number of risks/costs
mentioned number
10. Conflicts of interest
Not specified 0
Mentioned but none 1
Declared or obvious 2
11. Funding of the trial
Not specified 0
Public 1
Private 2
Mixed 3
12. Involvement of funding agency
Not specified 0
Specified 1
13. How conflict of interest is viewed
Not mentioned 0
Negative 1
Positive 2
Neutral 3
14. Judgments and ratings
a. Tone of assessment of clinical trial outcomes
Negative valuation of results 1
Positive valuation of results 2
Neutral valuation of results 3
b. Frame (choose the one that best describes the article)
1. Descriptive (a purely descriptive account of clinical
trial with little or no context outside the technology/
research)
2. Descriptive with context (a descriptive account of
clinical trial placed in context of other research, history,
medical condition, herbal remedy, etc.)
3. Progress (a celebration of new development; break-
through; direction of history; conflict between progres-
sive/conservative-reactionary)
4. Economic prospect (economic potential; prospects
for investment and profits; R & D arguments)
5. Dissatisfaction (patients are dissatisfied with con-
ventional treatment because it has been ineffective, has
produced adverse effects, or is seen as impersonal, too
technologically oriented, and/or too costly)
6. Need for personal control (patients seek alternative
therapies because they see them as les authoritarian and
more empowering and as offering them more personal
autonomy and control over their health-care decisions)
7. Philosophical congruence (alternative therapies are
attractive because they are seen as more compatible with
patients' values, worldview, spiritual/religious philoso-
phy, or beliefs regarding the nature and meaning of health
and illness)
8. Ethical (call upon ethical principles; thresholds;
boundaries; distinctions between acceptable/unaccepta-
ble risks in discussions on known risks; dilemmas; profes-
sional ethics
9. Risks before the event (call for restraint in the face
of unknown risk; warning; unknown risks as anticipated
threats; catastrophe warnings)
10. Risks after the event (fatalism after the innovation;
having adopted the new technology/products a price may
well have to be paid in the future; no control any more
after the event)
11. Public accountability (call for public control; par-
ticipation; public involvement; regulatory mechanisms;
private versus public interests; openness of procedures;
transparency; justification of procedures)BMC Medicine 2008, 6:35 http://www.biomedcentral.com/1741-7015/6/35
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12. Globalization (call for global perspective; national
competitiveness within an economy or isolationism)
13. Profile/human interest story
15. Accuracy
This section examines the accuracy of the newspaper arti-
cle in its reporting of the trial.
a. What/who is cited as the main source of the informa-
tion?
The clinical trial journal article 1
The authors of the clinical trial 2
Other scientists/physicians/practitioners 3
A press release/conference 4
A company spokesperson 5
A secondary source (e.g. other newspaper/review
article) 6
Celebrities 7
Other commentators (please specify) 8
Not specified 0
b. Was the study described as randomized (this includes
the use of words such as randomly, random and randomi-
zation?
Not specified 0
Yes, accurately 1
Yes, inaccurately 2
c. Was the study described as double blind?
Not specified 0
Yes, accurately 1
Yes, inaccurately 2
d. Was use of placebo mentioned?
Not specified 0
Yes, accurately 1
Yes, inaccurately 2
e. Was there a description of withdrawals and dropouts?
Not specified 0
Yes, accurately 1
Yes, inaccurately 2
f. Was the sample size mentioned?
Not specified 0
Yes, accurately 1
Yes, inaccurately 2
g. What was the length of the clinical trial mentioned?
Not specified 0
Yes, accurately 1
Yes, inaccurately 2
h. Are there any significant technical/scientific errors in
the reporting? (Assume that there are no errors in the sci-
entific journal article)
None 1
1–3 2
>3 3
i. Overall, do the main claims made in the newspaper
article accurately reflect the research findings?
Negative 1
Neutral 2
Positive 3
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